Skip to main content

Integration of genetic signature and TNM staging system for predicting the relapse of locally advanced colorectal cancer

International Journal of Colorectal Disease volume 25, pages 1277–1285 (2010)Cite this article

Abstract

Purpose

To identify potential genetic markers in treated stage II–III colorectal cancer patients and predict 3-year tumor relapse using statistical models based on important clinical factors and significant genetic markers.

Methods

Gene expression profiling by cDNA-mediated Annealing, Selection, extension and Ligation assay was performed in a prospectively collected 95 stage II–III colorectal cancer patients with Fluorouracil-based adjuvant chemotherapy. We studied the gene expression level of 502 genes for patients with different outcomes. The prognostic effect of genetic signature was evaluated in multivariate analysis. We further integrated the genetic signature to clinical Classification of Malignant Tumors (TNM) staging system for predicting of 3-year tumor relapse.

Results

An 8-gene signature was identified to well discriminate patients with different treatment outcomes. An integrated risk factor, which including 8-gene signature and TNM staging has been developed. ROC curve revealed that our integrated risk factor was better than genetic signature or current sixth edition TNM staging system alone.

Conclusions

Our 8-gene signature was promising in predicting 3-year disease-free survival rate for locally advanced colorectal cancer. The integrated risk factor, which combining genetic signature with clinical TNM staging system may further improve the outcome prediction.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66

    Article  PubMed  Google Scholar 

  2. Greene FL, Page D, Fleming ID et al (eds) (2002) AJCC cancer staging manual, 6th edn. Springer, New York

    Google Scholar 

  3. Compton C, Greene F (2004) The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 54:295–308

    Article  PubMed  Google Scholar 

  4. O’Connell J, Maggard M, Ko C (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425

    Article  PubMed  Google Scholar 

  5. Bibikova M, Talantov D, Chudin E, Yeakley J, Chen J, Doucet D et al (2004) Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 165:1799–1807

    CAS  PubMed  Google Scholar 

  6. Haller A, Kanakapalli D, Walter R, Alhasan S, Eliason J, Everson R (2006) Transcriptional profiling of degraded RNA in cryopreserved and fixed tissue samples obtained at autopsy. BMC Clin Pathol 6:9

    Article  PubMed  Google Scholar 

  7. Illumina: Gene Expression on Sentrix Arrays: DASL Assay System Manual. Doc # 11175105 edn: Illumina Inc 2004

  8. Fan J, Yeakley J, Bibikova M, Chudin E, Wickham E, Chen J et al (2004) A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 14:878–885

    CAS  Article  PubMed  Google Scholar 

  9. Illumina. BeadStudio User Guide. vol Doc # 11179632 Rev A San Diego: Illumina Inc 2004

  10. Bolstad B, Irizarry R, Astrand M, Speed T (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185–193

    CAS  Article  PubMed  Google Scholar 

  11. Dunning M, Smith M, Ritchie M, Tavare S (2007) beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23:2183–2184

    CAS  Article  PubMed  Google Scholar 

  12. Chen H, Yu S, Chen C, Chang G, Chen C, Yuan A et al (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356:11–20

    CAS  Article  PubMed  Google Scholar 

  13. Jeong SY, Chessin DB, Schrag D, Riedel E, Wong WD, Guillem JG (2005) Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 97:1705–1706, author reply 6–7

    Article  PubMed  Google Scholar 

  14. Alvarado M, Jensen E, Yeatman T (2006) The potential role of gene expression in the management of primary and metastatic colorectal cancer. Cancer Control 13:27–31

    PubMed  Google Scholar 

  15. Barrier A, Boelle P, Roser F, Gregg J, Tse C, Brault D et al (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24:4685–4691

    CAS  Article  PubMed  Google Scholar 

  16. Bustin S, Dorudi S (2004) Gene expression profiling for molecular staging and prognosis prediction in colorectal cancer. Expert Rev Mol Diagn 4:599–607

    CAS  Article  PubMed  Google Scholar 

  17. Cardoso J, Boer J, Morreau H, Fodde R (2007) Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta 1775:103–137

    CAS  PubMed  Google Scholar 

  18. Wang Y, Jatkoe T, Zhang Y, Mutch M, Talantov D, Jiang J et al (2004) Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol 22:1564–1571

    CAS  Article  PubMed  Google Scholar 

  19. Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S et al (2008) A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA 105:19432–19437

    CAS  Article  PubMed  Google Scholar 

  20. Watanabe T, Kobunai T, Toda E, Kanazawa T, Kazama Y, Tanaka J et al (2007) Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray. Clin Cancer Res 13:415–420

    CAS  Article  PubMed  Google Scholar 

  21. Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R et al (2005) Gene-expression profiling predicts recurrence in Dukes’ C colorectal cancer. Gastroenterology 129:874–884

    CAS  Article  PubMed  Google Scholar 

  22. Eschrich S (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23:3526–3535

    CAS  Article  PubMed  Google Scholar 

  23. Wiese AH, Auer J, Lassmann S, Nahrig J, Rosenberg R, Hofler H et al (2007) Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect Prev 31:282–295

    CAS  Article  PubMed  Google Scholar 

  24. Gentner B, Wein A, Croner RS, Zeittraeger I, Wirtz RM, Roedel F et al (2009) Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res 29:67–74

    CAS  PubMed  Google Scholar 

  25. Theret N, Musso O, Campion JP, Turlin B, Loreal O, L’Helgoualc’h A et al (1997) Overexpression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastasis. Int J Cancer 74:426–432

    CAS  Article  PubMed  Google Scholar 

  26. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD (2005) Insulin-like growth factor polymorphisms and colorectal cancer risk. Canc Epidemiol Biomarkers Prev 14:1204–1211

    CAS  Article  Google Scholar 

  27. Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062

    Article  PubMed  Google Scholar 

  28. Sirvent A, Benistant C, Pannequin J, Veracini L, Simon V, Bourgaux JF et al (2010) Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene 29:1303–1315

    CAS  Article  PubMed  Google Scholar 

  29. Ingley E (2008) Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 1784:56–65

    CAS  PubMed  Google Scholar 

  30. Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L et al (2007) Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res 67:7907–7916

    CAS  Article  PubMed  Google Scholar 

  31. Moroni M, Soldatenkov V, Zhang L, Zhang Y, Stoica G, Gehan E et al (2004) Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res 64:7346–7354

    CAS  Article  PubMed  Google Scholar 

  32. Kang HJ, Kim HJ, Kim SK, Barouki R, Cho CH, Khanna KK et al (2006) BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells. J Biol Chem 281:14654–14662

    CAS  Article  PubMed  Google Scholar 

  33. Beischlag TV, Perdew GH (2005) ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J Biol Chem 280:21607–21611

    CAS  Article  PubMed  Google Scholar 

  34. Lofstedt T, Fredlund E, Noguera R, Navarro S, Holmquist-Mengelbier L, Beckman S et al (2009) HIF-1alpha induces MXI1 by alternate promoter usage in human neuroblastoma cells. Exp Cell Res 315:1924–1936

    Article  PubMed  Google Scholar 

  35. Taj MM, Tawil RJ, Engstrom LD, Zeng Z, Hwang C, Sanda MG et al (2001) Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells. Prostate 47:194–204

    CAS  Article  PubMed  Google Scholar 

  36. Camilleri-Broet S, Cremer I, Marmey B, Comperat E, Viguie F, Audouin J et al (2007) TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene 26:142–147

    CAS  Article  PubMed  Google Scholar 

  37. Tomasetto C, Regnier CH, Rio MC (1998) TRAF-4 expression in breast carcinomas. Am J Pathol 153:2007–2008

    CAS  PubMed  Google Scholar 

  38. Dejmek J, Leandersson K, Manjer J, Bjartell A, Emdin SO, Vogel WF et al (2005) Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res 11:520–528

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful for the assistance of W. Huang, G. Yan in preparing and collection of clinical data. This work was supported by the grants from Science and Technology Commission of Shanghai Municipality program KWZD0703, National Key Project for Basic Research (2004CB518605) and Chinese National Natural Science Fund for Distinguished Young Scholars (30625019).

Conflict of interest statement

The author(s) indicated no potential conflicts of interest.

Author information

Affiliations

  1. Department of Colorectal Surgery, Cancer Hospital, Fudan University, 270 Dong An Road, Shanghai, 200032, People’s Republic of China

    Junjie Peng & Sanjun Cai

  2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

    Junjie Peng & Sanjun Cai

  3. Chinese National Human Genome Center at Shanghai, 250 Bi Bo Road, Shanghai, 201203, People’s Republic of China

    Zhimin Wang, Haifeng Wang, Hongjie Huang & Wei Huang

  4. Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA

    Wei Chen & Yin Ding

Authors
  1. Junjie Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhimin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yin Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haifeng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hongjie Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sanjun Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Wei Huang or Sanjun Cai.

Additional information

Junjie Peng and Zhimin Wang contributed equally to this article.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Peng, J., Wang, Z., Chen, W. et al. Integration of genetic signature and TNM staging system for predicting the relapse of locally advanced colorectal cancer. Int J Colorectal Dis 25, 1277–1285 (2010). https://doi.org/10.1007/s00384-010-1043-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-010-1043-1

Keywords

  • Colorectal cancer
  • DASL
  • Genetic signature
  • Prognosis